MedTrace Logo

Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma

NCT07611149 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-05-28

No results posted yet for this study

Summary

The goal of this study is to evaluate the safety of a new type of CAR T-cell, UF-KURE-BCMA, for the treatment of patients with advanced multiple myeloma that has not responded to other therapies. The main question is whether the use of these new CAR T-cells is safe for patients with this condition. Secondarily, the study will also look at the response of myeloma to this therapy.

Conditions

  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory

Interventions

BIOLOGICAL

Administration of CAR T-cells at 3 different dose levels

The patients will receive one of 3 dose levels as outlined above.

Sponsors & Collaborators

  • CellServe LLC

    collaborator UNKNOWN

  • Roya Clinical

    collaborator UNKNOWN

  • Kure Cells, INC

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2028-09-30
Completion
2028-12-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07611149 on ClinicalTrials.gov